Last $9.62 USD
Change Today -0.25 / -2.53%
Volume 107.4K
RNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kenneth H. Fischbeck M.D.

Member of Scientific & Clinical Advisory Board, Prosensa Holding N.V.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 1 different organizations across 1 different industries.

See Board Relationships
----

Background*

Dr. Kenneth H. Fischbeck,,M.D. has been chief of the Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, USA since 1998. Dr. Fischbeck serves as Member of Scientific & Clinical advisory board of Prosensa Therapeutics B.V. In 2000 he was elected to the Institute of Medicine of the National Academy of Sciences. He serves on advisory boards for the Hereditary Disease Foundation, the Spinal Muscular Atrophy ...

Read Full Background

Corporate Headquarters*

J.H. Oortweg 21
Leiden, Zuid-Holland 2333 CH

Netherlands

Phone: 31 71 332 2100
Fax: 31 71 332 2088

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Associate's Degree
Harvard University
MD
Johns Hopkins University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNA:US $9.62 USD -0.25

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$249.8K
Mark J. Ahn Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$737.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROSENSA HOLDING NV, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.